Frederick L. Ruberg

Frederick L. Ruberg, MD, a prominent figure at Boston University and the Amyloidosis Center, discusses the critical impact of transthyretin cardiac amyloidosis on older Black and Hispanic individuals with heart failure. The conversation reveals stark racial and age disparities in prevalence, particularly among men over 75. Ruberg emphasizes the need for improved diagnostic practices that consider gender and ethnicity differences. Early detection strategies and advancements in therapy also take center stage, highlighting the importance of family testing to combat this growing health issue.

Frederick L. Ruberg, cardiologist and Thomas J. Ryan Professor at Boston University, explains transthyretin (ATTR) cardiac amyloidosis. He outlines how ATTR presents in older adults, when to suspect it, and advances in noninvasive diagnosis. He discusses standard heart-failure care, arrhythmia surveillance and anticoagulation, and new disease-modifying therapies that stabilize or reduce transthyretin production.